Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2013 - New Report Available
Global Markets Direct's, 'Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Spinal Muscular Atrophy (SMA), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Spinal Muscular Atrophy (SMA). Spinal Muscular Atrophy (SMA) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's...
View full press release